Afnan to FDA: Simplify Post-Approval Changes, Spur Innovation

21 CFR 314.70, and the process by which FDA reviews changes to already approved applications, needs a risk-based update, now. Consultant Ali Afnan, formerly with FDA, makes his case.

Share Print Related RSS
If you are not automatically redirected, follow this link:

Share Print Reprints Permissions

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments